Question 1

What peer-reviewed research supports Oova's hormone tracking technology?

Accepted Answer

Hills et al. (2023) published in Medicina analyzed 4,123 menstrual cycles from 1,233 users, demonstrating 95% confidence in identifying cycle phase from single LH and PdG measurements combined with age. The study is indexed in PubMed Central (PMC10384168) and includes co-authorship from Drexel University College of Medicine.

Question 2

How many cycles has Oova studied in total?

Accepted Answer

Across all published studies and conference presentations, Oova research encompasses over 25,000 cycles: 4,123 cycles in the peer-reviewed Medicina study (2023), 16,697 cycles in the ASRM 2024 BMI/PCOS study, 4,209 cycles in the ASRM 2023 progesterone timing study, plus additional cohorts in perimenopause (1,745 women), AMA (1,782 women), and PCOS screening (1,821 users) studies.

Question 3

How does Oova define ovulation in its research?

Accepted Answer

Across Oova studies, ovulatory cycles are defined as having an LH peak greater than 35 mIU/L AND a progesterone (PdG) rise of at least 6.5 ng/mL within 72 hours after the LH peak. This dual-hormone confirmation approach is more accurate than LH-only detection methods used by standard ovulation predictor kits.

Question 4

What did Oova's research find about PCOS and fertility tracking?

Accepted Answer

Multiple Oova studies examined PCOS: The ASRM 2024 study (16,697 cycles) found PCOS patients are twice as likely to experience anovulatory cycles and have significantly longer follicular phases. The MRSi 2022 study (1,821 users) found PCOS patients have significantly lower LH peaks than women without reproductive conditions. These findings suggest quantitative hormone tracking may help identify PCOS patterns.

Question 5

What makes Oova's perimenopause research unique?

Accepted Answer

Oova's October 2025 perimenopause staging study achieved 88.25% accuracy in classifying STRAW+10 stages using a machine learning model trained on daily hormone data from 1,745 women. The research discovered that STRAW-2 (late reproductive stage) has 4 distinct subclusters with unique hormone signatures, demonstrating that perimenopause is a spectrum of patterns rather than a single uniform transition.

Question 6

What hormones does Oova measure and what are the detection ranges?

Accepted Answer

Oova measures three reproductive hormones through urine: LH (luteinizing hormone) up to 80 mIU/mL, E3G (estrone-3-glucuronide, a urinary estrogen metabolite) up to 500 ng/mL, and PdG (pregnanediol-3-glucuronide, a urinary progesterone metabolite) up to 40 μg/mL. The technology uses lateral flow quantitative multiplexed immunoassay with gold nanoparticle detection and AI-powered smartphone image processing.

Question 7

Which institutions have collaborated on Oova research?

Accepted Answer

Oova has collaborated with researchers from Drexel University College of Medicine, Stanford University OB/GYN, Zucker School of Medicine at Hofstra/Northwell, Stony Brook University, LSU Health Sciences Center, IRMS at St. Barnabas, OC Fertility, and New Hope Fertility Center. Studies have been presented at ASRM (American Society for Reproductive Medicine), ACOG (American College of Obstetricians and Gynecologists), and The Menopause Society conferences.

Question 8

How does Oova's at-home testing compare to clinical laboratory testing?

Accepted Answer

A 2025 prospective study at New Hope Fertility Center validated Oova's at-home hormone testing against clinical serum standards during IVF stimulation cycles. The study found 92% concordance between urinary LH and serum LH measurements, and 93% correlation between urinary PdG (progesterone metabolite) and serum progesterone across 62 paired measurements. This demonstrates that Oova's quantitative urine testing delivers lab-grade accuracy comparable to blood testing.

Your Cart

Leading with science

Select Research Partners

Check out our most recent research

Daily hormone tracking reveals perimenopause isn't one transition, it's four distinct patterns hiding in plain sight, changing how we diagnose and treat this life stage

Using Daily Hormone Tracking to Uncover the Impact of Anxiety and Sleep on Perimenopausal Hormone Fluctuations

Understanding the Influence of BMI and Polycystic Ovary Syndrome (PCOS) on Menstrual Cycle and Ovulation Trends

Clinical Research

Defining Perimenopause Stages Through Hormone Patterns: A Proof of Concept

Using Daily Hormone Tracking to Uncover the Impact of Anxiety and Sleep on Perimenopausal Hormone Fluctuations

Early Progesterone Rise in the Follicular Phase: Predictor of Anovulation?

Remote Monitoring of Cycle Trends in Patients of Advanced Maternal Age

Understanding the Influence of BMI and PCOS on Menstrual Cycle and Ovulation Trends

Can Remote Fertility Hormone Testing Identify Patients with Reproductive Disorders?

Oova's white papers

Urine-Serum LH and PdG Correlation During IVF Stimulation: Validating At-Home Hormone Testing Against Serum Standards

Oova: A two-in-one at-home test for measuring Luteinizing Hormone and Progesterone.

Clinical Case Study: 29-year-old patient conceives naturally after monitoring two cycles with Oova

Clinical Case Study: Integrative Approach to Unexplained Infertility

Clinical Case Study: 45-year-old patient conceives naturally after monitoring three cycles with Oova

Let's collaborate on research to move women's health forward